Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
Lancet Diabetes Endocrinol
.
2022 Jun;10(6):384-385.
doi: 10.1016/S2213-8587(22)00134-6.
Authors
Olivier Chabre
1
,
Marie Muller
2
,
Justine Cristante
3
,
Jean-Luc Cracowski
4
,
Emmanuel Gay
5
Affiliations
1
Université Grenoble Alpes, Service d'Endocrinologie CHU Grenoble Alpes, Unité Mixte de Recherche INSERM-CEA-UGA UMR 1036, Grenoble F-38000, France. Electronic address: olivierchabre@chu-grenoble.fr.
2
Service d'Endocrinologie CHU Grenoble Alpes, Grenoble, France.
3
Université Grenoble Alpes, Service d'Endocrinologie CHU Grenoble Alpes, Unité Mixte de Recherche INSERM-CEA-UGA UMR 1036, Grenoble F-38000, France.
4
Université Grenoble Alpes Pharmacovigilance Department, INSERM UMR 1300-Laboratory HP2, Grenoble Alpes University, Grenoble, France.
5
Université Grenoble Alpes, Service de Neurochirurgie CHU Grenoble Alpes, Grenoble, France.
PMID:
35597254
DOI:
10.1016/S2213-8587(22)00134-6
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Hydrocortisone / therapeutic use
Imidazoles
Pituitary ACTH Hypersecretion* / drug therapy
Pyridines
Substances
Imidazoles
Pyridines
Osilodrostat
Hydrocortisone